U.S. markets closed

The NovoCure (NASDAQ:NVCR) Share Price Is Up 275% And Shareholders Are Boasting About It

Simply Wall St

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you can make more than 100%. For example, the NovoCure Limited (NASDAQ:NVCR) share price has soared 275% in the last three years. That sort of return is as solid as granite.

See our latest analysis for NovoCure

Because NovoCure is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

In the last 3 years NovoCure saw its revenue grow at 58% per year. That's well above most pre-profit companies. Along the way, the share price gained 55% per year, a solid pop by our standards. But it does seem like the market is paying attention to strong revenue growth. Nonetheless, we'd say NovoCure is still worth investigating - successful businesses can often keep growing for long periods.

Depicted in the graphic below, you'll see revenue and earnings over time. If you want more detail, you can click on the chart itself.

NasdaqGS:NVCR Income Statement, April 30th 2019

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

Pleasingly, NovoCure's total shareholder return last year was 63%. That gain actually surpasses the 55% TSR it generated (per year) over three years. These improved returns may hint at some real business momentum, implying that now could be a great time to delve deeper. Before spending more time on NovoCure it might be wise to click here to see if insiders have been buying or selling shares.

Of course NovoCure may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.